Checklist
Pre-submission checklist: What's breaking first-cycle reviews — and how to get ahead of it
First-cycle review failure is no longer a rare setback — it's a pattern. With the FDA issuing more than 350 Complete Response Letters since 2025 and EMA negative opinions rising sharply, even scientifically rigorous programs are falling short. The reason is rarely weak data. It's the breakdown of the integrated narrative holding that data together. Download the checklist to help your team assess your program through a regulator’s lens and identify risks that could derail first-cycle review before they reach a reviewer.
Key highlights
The five failure patterns documented in this checklist repeat across programs and therapeutic areas with striking consistency — and they are largely visible in advance. Among the most common:
This checklist offers a practical framework for integrated submission readiness — one that spans strategic regulatory alignment, CMC and quality execution, clinical and evidence strategy, and market access planning.
- CMC uncertainty undermining strong clinical results — manufacturing questions can erode reviewer confidence even when efficacy and safety data are solid, particularly in cell and gene therapy programs
- Label overreach and weak benefit-risk articulation — when commercial intent subtly outpaces the evidence base, or when clinical and safety sections tell subtly different stories, major review questions follow
- Cross-functional misalignments that no single team is positioned to catch — the gaps between functions, not within them, are where experienced regulators look first
This checklist offers a practical framework for integrated submission readiness — one that spans strategic regulatory alignment, CMC and quality execution, clinical and evidence strategy, and market access planning.
